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Targeted radionuclide therapy is based on systemic application of particle-emitting radio-
pharmaceuticals which are directed toward a specific tumor-associated target. Accumula-
tion of the radiopharmaceutical in targeted cancer cells results in high doses of absorbed
radiation energy whereas toxicity to non-targeted healthy tissue is limited.This strategy has
found widespread application in the palliative treatment of neuroendocrine tumors using
somatostatin-based radiopeptides. The folate receptor (FR) has been identified as a target
associated with a variety of frequent tumor types (e.g., ovarian, lung, brain, renal, and
colorectal cancer). In healthy organs and tissue FR-expression is restricted to only a few
sites such as for instance the kidneys.This demonstrates why FR-targeting is an attractive
strategy for the development of new therapy concepts. Due to its high FR-binding affin-
ity (KD <10−9 M) the vitamin folic acid has emerged as an almost ideal targeting agent.
Therefore, a variety of folic acid radioconjugates for nuclear imaging have been developed.
However, in spite of the large number of cancer patients who could benefit of a folate-based
radionuclide therapy, a therapeutic concept with folate radioconjugates has not yet been
envisaged for clinical application. The reason is the generally high accumulation of folate
radioconjugates in the kidneys where emission of particle-radiation may result in damage
to the renal tissue. Therefore, the design of more sophisticated folate radioconjugates
providing improved tissue distribution profiles are needed. This review article summarizes
recent developments with regard to a therapeutic application of folate radioconjugates. A
new construct of a folate radioconjugate and an application protocol which makes use of
a pharmacological interaction allowed the first preclinical therapy experiments with radio-
folates. These results raise hope for future application of such new concepts also in the
clinic.
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FOLATE RECEPTOR AND FOLIC ACID
Folate receptors (FRs) are glycoproteins with molecular weights
of 38–44 kDa which exist in several isoforms (1, 2). The FR-α and
the FR-β are both anchored in the cell membrane by a glycosyl-
phosphatidyl-inositol domain. The FR-α is expressed at a few
sites of normal epithelial membranes for instance in the proximal
tubule cells of the kidneys (3–5) and in a variety of solid cancer
types of epithelial origin (6). Cancer types with the highest fre-
quency of FR-α expression are ovarian (90%), endometrial (90%),
brain (90%), lung (78%), and renal carcinomas (75%) (6–9). On
the other hand, FR-expression in cancer of the head and neck
(52%), breast (48%), stomach (38%), and colon-rectum (32%)
was found at intermediate frequencies (6, 9). It is important to
recognize that the expression level of the FR-α on tumors may
have a prognostic value as it has been found to correlate with the
survival rate of the patients. In ovarian, endometrial and breast
carcinomas as well as in primary and metastatic colorectal can-
cer overexpression of the FR-α correlated with a worse survival
(10–13). In contrast, evaluation of a large number of non-small
cell lung cancers revealed that high FR-expression levels correlated
with a better survival (14).
The FR-β is found in the placenta and in normal hemato-
poietic tissue (e.g., spleen, thymus, and monocytes) (15, 16) but
also in hematopoietic malignancies such as acute and chronic
myelogenous leukemia (17) and on activated macrophages (16).
Targeting of the FR-β expressed on activated macrophages has
initially been associated primarily with targeting of inflamma-
tory diseases such as rheumatoid arthritis (9, 18, 19). How-
ever, the FR-β may have future implications also in the field
of oncology as a marker of tumor-associated macrophages (20,
21).
The vitamin folic acid binds with high affinity to the FR
(KD= 10−9 M) and hence, it can be used as a targeting ligand.
Compared to other (e.g., peptide- or protein-based) targeting
agents the use of folic acid provides several advantages (22).
Folic acid is small in size (441 Da) and accessible for chemi-
cal modification. Moreover it is relatively stable in solution of
a wide range of pH-values and at elevated temperatures (22).
Due to its function as a vitamin, folic acid is not toxic to healthy
organs and tissue nor does it provoke immune reactions. Since
binding to the FR results in an endocytotic uptake of folic
acid cellular delivery of even larger payloads which are conju-
gated to folic acid is accessible (23, 24). All of these features
together make folic acid an excellent candidate for tumor targeting
allowing selective delivery of attached probes to FR-expressing
(cancer) cells.
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FR-TARGETED THERAPIES
In the first instance it is the FR-α which attracted most inter-
est as a tumor-associated target for imaging purposes and tar-
geted therapy concepts (9, 25). Targeting of FR-positive tumor
cells in vitro and in vivo has been exemplified by a number
of research groups using folic acid conjugates with a vari-
ety of therapeutic probes (25, 26). For FR-targeted therapies
several concepts have been developed based on e.g., highly toxic
chemotherapeutics, drug-loaded liposomes, nanoparticles, and
oligonucleotides which were attached to folic acid [reviewed
in (27)]. Among those the most advanced approach is clearly
the concept of using folic acid-targeted chemotherapeutics,
most importantly EC145, a folate conjugate of a vinca alka-
loid, desacetylvinblastine monohydrazide (28). Already in 2009
a phase I clinical study was published reporting on the clinical
pharmacokinetics and exposure-toxicity relationship of EC145
in cancer patients (29). Meanwhile, several clinical studies per-
formed with EC145 (Vintafolide™) demonstrated the bene-
fit of this therapy for patients with cancer of the lung and
ovaries (30–33)
For FR-targeted immunotherapy as another targeted therapy
concept folic acid is exploited to carry an attached hapten to the
surface of tumor cells (34). The aim of this approach is to render
the tumor cells more immunogenic upon FR-binding of the folate-
hapten conjugates. The pre-existing or induced immunity of the
patient allows the haptens to attract anti-hapten-antibodies and
to provoke immune reactions. Hence, it enhances the anticancer
immune reaction of the host against hapten-decorated tumor cell
(34). Several preclinical studies proved the potential of this con-
cept for cancer therapy (35–37). Another strategy of FR-targeted
immunotherapy is the use of FR-binding antibodies (38, 39). Sev-
eral concepts of (radio)immunotherapy with FR-binding chimeric
(e.g., MOv18) and humanized (e.g., MORAb-003) monoclonal
antibodies were developed and evaluated in (pre)clinical studies
(38, 40–44).
Various different drugs, including chemotherapeutics (e.g.,
doxorubicin and paclitaxel) have been selectively delivered to FR-
expressing cancer cells through use of folic acid conjugated carriers
such as liposomes and nanoparticles (26, 45, 46). Possible advan-
tages of this strategy are an increased drug loading capacity and
the fact that the larger size of these targeting constructs prevents
renal filtration and hence, undesired retention in the kidneys (27).
From in vivo investigations with FR-targeted carriers labeled with
radionuclides (99mTc, 188Re, 68Ga, 64Cu) (47–50) it is apparent that
nanoparticles and liposomes usually accumulate in the reticuloen-
dothelial system (RES) while the in vivo targeting effect remains
poor (47, 48).
GENERAL FEATURES OF FOLATE RADIOPHARMACEUTICALS
In the last two decades our group and others have focused
on the development of folate-based radiopharmaceuticals (51).
The aim was to design new tools for nuclear imaging of FR-
positive cancer via single photon emission computed tomo-
graphy (SPECT) and positron emission tomography (PET) (52–
54). More recently, several endeavors were undertaken in view
of a therapeutic application of folate radioconjugates using
particle-emitting radioisotopes (55–57).
A general feature of folate-based radiopharmaceuticals is their
specific accumulation in FR-positive tumor (xeno)grafts. How-
ever, accumulation of radioactivity is also always seen in FR-
positive organs and tissue such as the kidneys, the salivary glands,
and the choroid plexus (58). The distribution profile of radio-
folates varied according to their chemical structure with one of
the most important feature being a highly hydrophilic charac-
ter (54). In all of the cases undesired accumulation of radiofo-
lates was found in the renal cortex where the FR is expressed in
the proximal tubule cells of the brush border membrane (3, 5,
58). These circumstances resulted in commonly low tumor-to-
kidney ratios (<0.2) of radiofolates. This situation is undesired in
view of a therapeutic application because of the inherent risk of
damage to the radiosensitive kidneys by a high dose burden from
particle-radiation (56).
STRATEGIES TO IMPROVE THE TISSUE DISTRIBUTION OF
RADIOFOLATES
A high radioactivity dose burden to the kidneys and as a con-
sequence the risk of damage to the radiosensitive renal tissue
particularly in patients with hypertension, diabetes, or other
risk factors is an issue in the course of targeted radionuclide
therapy (59, 60). Administration of high dosed amino acids,
usually lysine and arginine, is a means applied in the clinics to
reduce unspecific accumulation of radiopeptides (e.g., somato-
statin analogs) in the kidneys (61). However, this strategy is not
applicable for folate radioconjugates since other than in the case
of radiopeptides, renal accumulation is specific due to binding
of radiofolates to FRs (56). Application of diuretics or acidi-
fication of the urine did also not have a positive impact on
renal retention of radiofolates (56). Therefore, alternative strate-
gies are required. In the first approach antifolates were applied
in combination with radiofolates with the aim to improve the
tissue distribution profile of radioactivity (62, 63). In a second
approach the folate conjugate’s backbone was modified with an
albumin-binding entity in order to enhance the circulation time
in the blood and therewith possibly increase the tumor-to-kidney
ratio (64).
APPLICATION PROTOCOL OF RADIOFOLATES COMBINED WITH
PEMETREXED
The effects of three clinically used antifolates [methotrexate,
raltitrexed, and pemetrexed (65), Figure 1] were investigated in
combination with a 99mTc(CO)3-labeled folate conjugate with the
aim to increase the tumor uptake of the radiofolate (62). This study
design was based on the observation that incubation of cancer cells
with antifolates resulted in an increased uptake of radiofolates
in vitro (62, 66).
The in vivo data showed that the accumulation of the radio-
folate in KB tumor xenografts remained unaffected but a signifi-
cantly reduced uptake of radioactivity was found in the kidneys.
This resulted in clearly improved tumor-to-kidney ratios, with the
best results obtained with pemetrexed (Figure 2) (62, 67).
The same effect was successfully reproduced in different
tumor mouse models (KB, IGROV-1, and SKOV-3 tumors
in nude mice and M109 tumors in Balb/c mice) and
variable folate radioconjugates [99mTc(CO)3-folate, 99mTc-EC20,
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FIGURE 1 | Folic acid and antifolates. Chemical structures of (A) folic acid
and the antifolates (B) methotrexate, (C) raltitrexed (Tomudex™ ), and
(D) pemetrexed (Alimta™ ).
FIGURE 2 | Effects of antifolates on the tumor-to-kidney ratios of
radiofolates. Tumor-to-kidney ratios obtained at 1 and 4 h after injection of
99mTc(CO)3-folate alone (green) or in combination with pre-injected
methotrexate (blue), raltitrexed (red), or pemetrexed (yellow).
111In-DTPA-folate, 111In/177Lu-DOTA-click-folate, 67Ga-DOTA-
Bz-folate (67Ga-EC0800), 68Ga-NODAGA-folate] (55, 62, 63, 67–
69). The injection protocol and the related SPECT/CT images
using 177Lu-EC0800 are shown in Figure 3. The underlying
mechanism of this effect is not yet clear but a topic of cur-
rent investigations in our laboratories. The combination of folate
radioconjugates and pemetrexed is, however, appealing in view
of a therapeutic application. In this respect, we hypothesized
that pemetrexed would have a dual role if it was combined with
folate-based radionuclide therapy. On one hand it would reduce
undesired renal uptake of radiofolates and on the other hand it
may have an effect as a chemotherapeutic (70, 71) or radiosen-
sitizing agent (72–74) on the tumor tissue and thus enhance the
therapeutic efficacy on the tumors.
DESIGN OF A FOLATE CONJUGATE WITH AN ALBUMIN-BINDING
ENTITY
Increasing the serum half-life of pharmaceuticals by serum pro-
tein binding may be a measure to improve the pharmacokinetic
properties of otherwise rapidly cleared molecules (75). Based on
the results which are reported in the literature with antibody
fragments that exhibited a non-covalent association with serum
proteins (76, 77), it was hypothesized that albumin-binding prop-
erties would improve the tissue distribution of radiofolates as
well. Therefore, a DOTA-folate conjugate was developed with an
integrated small-molecular weight albumin-binding entity which
was previously identified from a DNA-encoded chemical library
based on the lead structure 4-(p-iodophenyl)butyric acid (78).
This novel DOTA-folate conjugate (cm09, Figure 4B) was fully
evaluated in its 177Lu-labeled version and compared with the
data obtained with a conventional 177Lu-labeled DOTA-folate
conjugate (177Lu-EC0800, Figure 4A) (64).
The in vitro cell uptake properties of 177Lu-cm09 were compa-
rable to those of other folate radioconjugates (64). Different was
however, its feature of binding to plasma proteins as demonstrated
by an in vitro assay (64). In vivo biodistribution studies were per-
formed with 177Lu-cm09 and 177Lu-EC0800 in athymic nude mice
bearing KB tumor xenografts (Figure 5). The enhanced blood
circulation time of 177Lu-cm09 compared with 177Lu-EC0800
resulted in a tumor accumulation of 177Lu-cm09 which was∼2.5-
fold higher (∼18% ID/g, 4 h p.i.) than the uptake of 177Lu-EC0800
(∼7.5% ID/g, 4 h p.i.) (64). On the other hand, renal retention
of 177Lu-cm09 was relatively low (∼28% ID/g, 4 h p.i.) com-
pared to other folate conjugates that lack an albumin-binding
entity such as 177Lu-EC0800 (>70% ID/g, 4 h p.i.) (64). These
findings resulted in a sevenfold improved tumor-to-kidney ratio
(∼0.7, 4 h p.i.) for 177Lu-cm09 compared to the ratio obtained
with 177Lu-EC0800 (∼0.1, 4 h p.i.). The excellent in vivo proper-
ties of 177Lu-cm09 opened new perspectives for the development
of folate-based radionuclide therapy.
To further improve the tumor-to-kidney ratio of the long-
circulating 177Lu-cm09, biodistribution studies were performed
with 177Lu-cm09 and pemetrexed using KB tumor-bearing mice.
Pemetrexed was administered according to the same application
protocol as it was previously employed with conventional folate
radioconjugates (55, 63, 67). Independent on whether or not
pemetrexed was pre-injected, the tumor uptake was about ∼18%
ID/g 4 h after injection. In contrast, reduced renal accumulation
(16.81± 2.25% ID/g) of radioactivity was found 4 h after injec-
tion of 177Lu-cm09 if it was combined with pemetrexed compared
to the amount of accumulated 177Lu-cm09 if it was applied as a
single agent (28.05± 1.35% ID/g, 4 h p.i.) (64). Thus, pre-injected
pemetrexed increased the tumor-to-kidney ratio (1.07± 0.25, 4 h
p.i) compared to control values at the same time after injec-
tion of 177Lu-cm09 (0.65± 0.07, 4 h p.i.). However, at later time
points after injection of 177Lu-cm09 the kidney reducing effect of
pemetrexed was not observed anymore (64). Most probably, these
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FIGURE 3 | Effect of pemetrexed on the tissue distribution of
radiofolates. Injection scheme (left) and whole-body SPECT/CT
images of KB tumor-bearing mice 24 h after injection of
177Lu-EC0800 (right). (A) Injection of only 177Lu-EC0800 (20 MBq)
and corresponding SPECT/CT image. (B) Injection of 177Lu-EC0800
(20 MBq, Figure 4A) and PMX (0.4 mg) and corresponding
SPECT/CT images. Tumors and kidneys are indicated with white and
yellow arrows.
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FIGURE 4 | DOTA-folate conjugates. Chemical structures of (A) EC0800 (56, 64) and (B) cm09 (64).
findings were a result of the fact that pemetrexed was more quickly
cleared from the blood circulation than 177Lu-cm09. Therefore,
the pemetrexed related effect to reduce the kidney uptake of 177Lu-
cm09 was not maintained for the fraction of 177Lu-cm09 which
was still in the blood circulation when pemetrexed was already
excreted (64).
FOLATE RECEPTOR TARGETED RADIONUCLIDE
THERAPY – FIRST RESULTS
Both of the aforementioned approaches, a pharmacological inter-
vention with pemetrexed and a chemical modification of the folate
conjugate with an albumin-binding entity resulted in improved
tissue distribution profiles of radioactivity. Employing either of
these approaches for radionuclide therapy in a preclinical setting
was the subject of recent research activities in our laboratories.
The decay properties of the therapeutic radionuclides which were
employed for these studies are listed in Table 1.
IN VIVO COMBINATION THERAPY OF PEMETREXED AND 177LU-EC0800
In a recent study the combined application of 177Lu-EC0800
(Figure 3A) and pemetrexed (Figure 1D) was investigated using
KB tumor-bearing nude mice (79). Four groups of six athymic
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FIGURE 5 | Comparison of the tissue distribution of 177Lu-EC0800 and
177Lu-cm09. Biodistribution data 4 and 24 h after injection of 177Lu-EC0800
and 177Lu-cm09 in athymic nude mice, bearing KB tumor xenografts.
Table 1 |Therapeutic radioisotopes used for folate-based radionuclide
therapy.
Isotope 177Lu 161Tb 149Tb
Half-life 159.4 h 165.4 h 4.12 h
Eα – – 3.967 MeV (16.7%)
E β−(av) 0.134 MeV (100%) 0.154 MeV (100%) 0.730 MeV
Eγ (intensity) 112.9 keV (6.17%) 25.7 keV (23.2%) 165.0 keV (26%)
208.4 keV (10.4%) 48.9 keV (17.0%) 352.2 keV (29%)
74.6 keV (10.2%) 388.6 keV (18%)
652.1 keV (16%)
nude mice with KB tumor xenografts received only saline (group
A),pemetrexed at a high dose (2× 0.8 mg,group B), 177Lu-EC0800
(1× 20 MBq),and pemetrexed at a low dose (1× 0.4 mg) to reduce
renal uptake (group C) or 177Lu-EC0800 (1× 20 MBq) and a high
dose of pemetrexed (2× 0.8 mg, group D). Application of even
a high dose of pemetrexed alone had almost no effect on tumor
growth in mice of group B, compared with control animals of
group A (Figure 6A). However, the application of 177Lu-EC0800
resulted in a tumor growth delay (group C) which was increased
if it was combined with a high dose of pemetrexed (group D)
(Figure 6A). The therapeutic effect of 177Lu-EC0800 was also
reflected by the increased average survival time of mice (group
C: 30 days) compared to control mice (group A: 20 days) and mice
which received only pemetrexed (group B: 24.5 days) (Figure 6B)
(79). However, the clearly most favorable therapy protocol was
the combination of 177Lu-EC0800 with a high dose of pemetrexed
(group D) which resulted in an average survival time of 35 days
(Figure 6B) (79).
These findings indicated a radiosensitizing effect of pemetrexed
as it was previously reported in other in vitro and in vivo studies
that combined pemetrexed with external radiation therapy (72,
73, 80, 81). An additional study was conducted with non-tumor-
bearing mice over a time period of several months to investigate
the potential impairment of the kidneys. It was demonstrated that
pemetrexed was able to protect kidneys from radio-nephrotoxicity
(79). Further and more detailed studies will be warranted to inves-
tigate the utility of this combination in view of a potential clinical
application.
FOLATE RECEPTOR TARGETED RADIONUCLIDE TUMOR THERAPY USING
177LU-CM09
The first published therapy experiment with a folate radiocon-
jugate was performed with KB tumor-bearing nude mice using
177Lu-cm09 (64). Groups of five mice each were treated with
only saline (group A) or with the unlabeled DOTA-folate cm09
(group B). One group received 177Lu-cm09 in a single injection
of 20 MBq (group C), another group received two injections of
10 MBq each (group D) and the last group received three injec-
tions of 7 MBq each (group E) (Figure 7A). The individual body
weight and tumor volume was measured every other day. The
results showed a constant tumor growth in mice of groups A
and B which did not receive radioactivity (Figure 7B). In all
mice of groups C to E tumor growth was clearly delayed with
the best effect achieved in mice of group C which had been
injected with the whole amount of 20 MBq 177Lu-cm09 in one
single injection (Figure 7B). The average survival time of con-
trol mice of group A and group B was 27 and 24 days, respec-
tively, whereas an almost doubled survival time was observed
for mice of groups D and E (48 and 46 days, respectively). In
mice which received 20 MBq 177Lu-cm09 in one single injec-
tion the tumors disappeared completely in four of five mice
and hence these four mice were still alive at the end of the
study which prevented the determination of an average survival
time (64).
FOLATE RECEPTOR TARGETED α- AND β-RADIONUCLIDE TUMOR
THERAPY USING 149/161TB-CM09
By using the same DOTA-folate conjugate (cm09, Figure 4B) as
previously employed with 177Lu (64) a pilot therapy study was per-
formed with therapeutic terbium radioisotopes (82). 161Tb decays
by the emission of β-particles and provides similar decay prop-
erties to 177Lu (Table 1) (82, 83). 149Tb decays by emission of
short-ranged α-particles with a half-life of 4.12 h (Table 1) (82).
Since the availability of 149Tb was limiting in this study the exper-
iments were performed with only a small number of mice bearing
KB tumor xenografts.
In the α-therapy study, three mice received only saline (group
A) and three mice received twice an injection of 1.1 and 1.3 MBq
of 149Tb-cm09, respectively (group B). In two of the treated
mice the tumor growth was clearly delayed and in one mouse
the tumors disappeared completely (Figure 8A). Compared to
untreated control mice of group A, the average survival time
was significantly prolonged (p< 0.05) in mice of group B. The
β−-therapy study was carried out with five mice which received
only saline (group A) and another five mice which received
www.frontiersin.org September 2013 | Volume 3 | Article 249 | 5
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FIGURE 6 | Graphs of tumor growth and survival. Preclinical study
with athymic nude mice bearing KB tumor xenografts. (A) Relative
tumor size and (B) survival rate of mice of group A (control), group B
(2×0.8 mg pemetrexed), group C (20 MBq 177Lu-EC0800 and 0.4 mg
pemetrexed), and group D (20 MBq 177Lu-EC0800 and 2×0.8 mg
pemetrexed).
FIGURE 7 | Design and results of the therapy study. (A) Application
protocol and (B) average relative tumor size for mice of groups A–E. This
research was originally published in Ref. (64). ©by the Society of Nuclear
Medicine and Molecular Imaging, Inc.
11 MBq of 161Tb-cm09 (group B). The overall survival time of
control mice was 28 days. In four of the five treated mice of
group B, KB tumors disappeared completely and hence these
mice were still alive at day 56 when the study was terminated
(Figure 8B).
The results obtained with 177Lu-cm09 and 149/161Tb-cm09
indicated the potential of FR-targeted radionuclide therapy by
using folic acid as a targeting ligand. Although the therapy regimes
reported in these studies were well tolerated by the test animals,
there is a potential risk of damage to the kidneys by particle-
radiation. Therefore, kidney function was monitored in a pre-
liminary study over 6 months in non-tumor-bearing mice which
received 177Lu-cm09 (20 MBq/mouse) (unpublished data). Blood
FIGURE 8 | Graphsof tumor growth from each individual mouse.
(A) Relative tumor size of mice of the α-radionuclide therapy study (a1–a3:
control mice; b1–b3: mice treated with 149Tb-cm09). (B) Relative tumor size
of mice of the β−- radionuclide therapy study (c1–c5: control mice; d1–d5:
161Tb-cm09 treated mice). This research was originally published in Ref. (82).
©by the Society of Nuclear Medicine and Molecular Imaging, Inc.
plasma parameters were analyzed and quantitative SPECT exper-
iments using 99mTc-DMSA were performed to estimate poten-
tial impairment of kidney function as previously reported (84).
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Although signs of radio-nephrotoxicity were not observed, more
recent investigations indicate long-term impairment of the kidney
function if higher amounts of folate radioconjugates are admin-
istered. Hence, further preclinical studies with larger cohorts of
mice will be clearly necessary to provide more detailed information
about the suitability of this therapy concept.
FOLATE RECEPTOR TARGETED RADIONUCLIDE TUMOR THERAPY USING
RADIOACTIVE LIPOSOMES
In terms of radionuclide therapy the approach of using liposome-
or nanoparticle-based carriers for passive or targeted delivery
of particle-emitting radionuclides to cancer cells is scarcely
reported in the literature but has recently been reviewed by
Sofou (85). It could be in particular attractive for radionu-
clides that are inappropriate for direct complexation by con-
ventional chelation concepts (86). An example that made use
of folic acid decorated liposomes as carriers for the α-emitting
radionuclides radium (223Ra) and actinium (225Ac) has been
reported by Larsen and Co-workers (87). The radioactive lipo-
some formulations possessed binding properties to FR-expressing
cancer cells in vitro and were stable in serum with only low
release of radionuclides. Hence, this or similar approaches
may have the potential for an in vivo translation in the
future.
STABILITY, RADIOLYSIS, TOXICITY, AND SAFETY ASPECTS OF
FOLATE-BASED RADIOCONJUGATES
Folate radioconjugates were found to be very stable in PBS and
blood plasma at 37°C with only marginal release of radiometals
over time (56). 177Lu-cm09 showed a particularly high in vitro sta-
bility with>99% intact product over 6 days in human plasma (64).
Little is known about potential radiolysis of folate radioconjugates
(64). However, since there are studies reporting on the degrada-
tion of folate molecules exposed to high temperatures, ultraviolet
light, and oxygen (88–90) it is likely that radiolytic processes would
occur in highly active formulations of radiofolates. In view of a
clinical application of therapeutic folate radioconjugates extensive
investigations will be required with respect to the stabilization of
radioconjugates by using quenchers such as for instance ethanol
and ascorbic acid.
Since folic acid and folates are essential nutritions for the
human organism and can be administered by supplements in
mg-amounts, folate derivatives are expected to be well tolerated
even if they were applied for radiotherapeutic purposes, where the
injected amount would not exceed about 200µg. Nevertheless,
the high uptake of folate radioconjugates in the kidneys is of con-
cern in terms of long-term radionephropathy caused by particle-
radiation if the folate conjugates were used for radionuclide
therapy as mentioned above.
CHALLENGES FOR CLINICAL TRANSLATION AND FUTURE
PERSPECTIVES
For a clinical translation of the “pemetrexed protocol” in combi-
nation with therapeutic radiofolates it will be crucial to answer
the question on whether pemetrexed would have the same kidney
reducing effect of radiofolates in man than it has in mice. Given
that this would be the case a further critical point may be the
fact that pemetrexed is not yet approved for ovarian, endometrial,
and cervical cancer, which are the tumor types with the highest
FR-expression level (6, 9). At the moment non-small cell lung
cancer would clearly be the ideal candidate for this combination
because of frequent FR-expression in this cancer type and the FDA-
approved indication of pemetrexed for the treatment of non-small
cell lung cancer (91–93). However, preclinical results of this com-
bination in a lung tumor mouse model will be required to confirm
the applicability of this approach also in other than cervical and
ovarian tumors types.
The development of a folate conjugate which was chemically
modified with an albumin-binding entity meant a significant step
forward in the development of a folate radioconjugates for ther-
apeutic applications (64). Excellent results were achieved with
177Lu-cm09 and 149/161Tb-cm09 in terms of tumor growth inhi-
bition and tolerability in mice (64, 82). For a safe application of
targeted radionuclide therapy the tumor-to-kidney ratio of accu-
mulated radioactivity should be above one. In this respect, it
has to be critically acknowledged that the uptake and retention
of radiolabeled cm09 in the kidneys is still high relative to the
tumor uptake. This aspect needs to be considered with regard to
a potential clinical translation of this approach. Future develop-
ment must clearly focus on alteration of the tracer design. Such an
intervention is expected to result in an improved tissue distribu-
tion profile with respect to an increased tumor-to-kidney ratio of
radioactivity.
SUMMARY AND CONCLUSION
Targeted radionuclide therapy showed impressive results for the
palliative treatment of cancer such as neuroendocrine tumors.
Due to the large number of tumor types which overexpress the
FR and the ideal characteristics of folic acid as a targeting lig-
and the development of therapeutic folate radioconjugates holds
great promise for the management of cancer diseases in the
future. The drawback of a high renal accumulation of conven-
tional radiofolates can largely be overcome by co-application of
the antifolate pemetrexed or by a chemical modification of the
folate radioconjugate with an albumin-binding entity. Both strate-
gies resulted in significantly increased tumor-to-kidney ratios
and hence, allowed the performance of preclinical therapy stud-
ies using particle-emitting isotopes. Application of 177Lu-EC0800
benefited from the co-administered pemetrexed not only in that
it reduced undesired kidney uptake but also by an enhanced anti-
cancer effect which was mediated by pemetrexed’s action as a
chemotherapeutic agent. Nevertheless, application of a chemi-
cally modified folate radioconjugate with optimized tissue dis-
tribution characteristics is more likely translatable to a clinical
setting than the combination with a chemotherapeutic agent.
We believe that a further improvement of the tracer design will
finally allow application of FR-targeted radionuclide therapy in
patients.
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